IMDX
Insight Molecular Diagnostics Inc.
Next earnings Aug 10, 2026 · consensus $-0.25 EPS, $446K rev
Last earnings +2.4% on 2026-05-13
$5.40
▼ -3.40%$5.40▲ +27.36%
over 1Y
L $2.40EODHDH $8.48
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.4%
1W+0.0%
1M-15.8%
3M+51.7%
YTD-24.6%
1Y+27.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Revenue grew 115.6% YoY; but unprofitable (net margin -1238.5%).
Insight Molecular Diagnostics Inc. shows $4.05M in FY2025 revenue (+115.6% YoY), a -1238.5% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.20M | $958K | $1.50M | $1.88M | $4.05M |
| Gross profit | $1.42M | -$18.0K | $413K | $740K | $2.30M |
| Operating income | -$53.7M | -$18.0M | -$25.1M | -$61.0M | -$51.1M |
| Net income | -$64.1M | -$72.9M | -$27.8M | -$60.7M | -$50.2M |
| Diluted EPS | — | -$13.25 | -$3.75 | -$4.66 | -$1.65 |
| Net margin | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$164M
EV / EBITDA—
EV / Sales40.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-28.9%
FCF yield-14.6%
Quality & risk
ROIC (est.)—
Free cash flow-$25.4M
Total debt$1.87M
Net cash$9.71M
Altman Z-Score-26.20 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+12.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-112026-06-17open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗8-K/APeriod ending 2026-02-202026-05-13open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEFA14AFiling2026-04-30open ↗DEF 14APeriod ending 2026-04-302026-04-30open ↗8-KPeriod ending 2026-04-302026-04-30open ↗SCHEDULE 13D/AFiling2026-04-27open ↗
Frequently asked
- Is Insight Molecular Diagnostics Inc. (IMDX) a buy?
- IMDX currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 115.6% YoY; but unprofitable (net margin -1238.5%).
- What is Insight Molecular Diagnostics Inc.'s quality score?
- IMDX scores 35.29411764705882/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001642380, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 7:37:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.